Jump to main content
Jump to site search

Issue 1, 2018

Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

Author affiliations

Abstract

An effective chemotherapy is usually subject to an insufficient loading of hydrophobic drugs as well as severe side effects. In order to address these dilemmas in one formulation, we herein construct paclitaxel prodrug based mixed micelles (MMs) for tumor-targeted chemotherapy. The paclitaxel prodrug containing a hydrophobic PTX and a hydrophilic PEG chain can self-assemble into uniform MMs with distearoyl phosphoethanolamine–polyethylene glycol–folate (DSPE–PEG–FA). The resultant MMs with preferable stability and hemolysis compatibility could improve the cellular uptake of nanoparticles via FA receptor-mediated endocytosis as compared to the single micelles (SMs). This tumor targetability was also confirmed in vivo by fluorescent imaging. MMs with a stable drug loading as well as tumor targetability displayed elevated in vitro cytotoxicity and in vivo antitumor efficacy compared with Taxol, which could be a potential formulation for cancer therapy.

Graphical abstract: Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

Associated articles

Supplementary files

Article information


Submitted
15 Jul 2017
Accepted
01 Dec 2017
First published
02 Jan 2018

This article is Open Access

RSC Adv., 2018,8, 380-389
Article type
Paper

Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy

D. Tang, X. Zhao, T. Yang and C. Wang, RSC Adv., 2018, 8, 380 DOI: 10.1039/C7RA07796C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.


Social activity

Search articles by author

Spotlight

Advertisements